Stay updated on DUET Clinical Trial: Sparsentan in FSGS.
Sign up to get notified when there's something new on the DUET Clinical Trial: Sparsentan in FSGS. page.

Latest updates to the DUET Clinical Trial: Sparsentan in FSGS. page
- Check5 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAn NIH-wide notice about changes in terminology appears above the 403 error page, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check47 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous detailed content of the trial. This blocks access to sections like study details, interventions, eligibility criteria, and locations, leaving only an error screen with a Home link.SummaryDifference19%

- Check54 days agoChange DetectedRevision label on the page updated from v3.6.6 to v3.7.0, reflecting a platform maintenance release. It does not modify study data or text.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page’s Revision tag was updated from v3.6.5 to v3.6.6, indicating a new version of the page. This change affects only the metadata label and does not modify the substantive study details.SummaryDifference0.0%

Stay in the know with updates to DUET Clinical Trial: Sparsentan in FSGS.
Enter your email address, and we'll notify you when there's something new on the DUET Clinical Trial: Sparsentan in FSGS. page.